Therefore, we and others have proposed that the monoclonal antibody Denosumab (which specifically inhibits RANK/RANKL interactions) could potentially be used for the prophylactic treatment of breast cancer in BRCA1/2 carriers (42). This evidence concerns the gene TNFSF11 and breast carcinoma.